Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer

Lookup NU author(s): Dr Mark Wade, Dominic Jones, Laura WilsonORCiD, Dr Jacqueline Stockley, Dr Kelly CoffeyORCiD, Professor Craig RobsonORCiD, Dr Luke GaughanORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

Endocrine therapy has successfully been used to treat estrogen receptor (ER)-positive breast cancer, but this invariably fails with cancers becoming refractory to treatment. Emerging evidence has suggested that fluctuations in ER co-regulatory protein expression may facilitate resistance to therapy and be involved in breast cancer progression. To date, a small number of enzymes that control methylation status of histones have been identified as co-regulators of ER signalling. We have identified the histone H3 lysine 9 mono- and di-methyl demethylase enzyme KDM3A as a positive regulator of ER activity. Here, we demonstrate that depletion of KDM3A by RNAi abrogates the recruitment of the ER to cis-regulatory elements within target gene promoters, thereby inhibiting estrogen-induced gene expression changes. Global gene expression analysis of KDM3A-depleted cells identified gene clusters associated with cell growth. Consistent with this, we show that knock-down of KDM3A reduces ER-positive cell proliferation and demonstrate that KDM3A is required for growth in a model of endocrine therapy-resistant disease. Crucially, we show that KDM3A catalytic activity is required for both ER-target gene expression and cell growth, demonstrating that developing compounds which target demethylase enzymatic activity may be efficacious in treating both ER-positive and endocrine therapy-resistant disease.


Publication metadata

Author(s): Wade MA, Jones D, Wilson L, Stockley J, Coffey K, Robson CN, Gaughan L

Publication type: Article

Publication status: Published

Journal: Nucleic Acids Research

Year: 2015

Volume: 43

Issue: 1

Pages: 196-207

Print publication date: 01/01/2015

Online publication date: 08/12/2014

Acceptance date: 29/11/2014

Date deposited: 14/12/2015

ISSN (print): 0305-1048

ISSN (electronic): 1362-4962

Publisher: Oxford University Press

URL: http://dx.doi.org/10.1093/nar/gku1298

DOI: 10.1093/nar/gku1298


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Newcastle University
12-0199Worldwide Cancer Research

Share